![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 7, 4597-4600, February 15, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
, andFrom the Department of Pharmacology, Medical College of Ohio, Toledo, Ohio 43614
Received for publication, September 14, 2001, and in revised form, December 6, 2001
| |
ABSTRACT |
|---|
|
|
|---|
We have identified a new first step in the
hormonal activation of the glucocorticoid receptor (GR). Rather than
causing immediate dissociation of the cytoplasmic GR heterocomplex,
binding of hormone-induced substitution of one immunophilin (FKBP51)
for another (FKBP52), and concomitant recruitment of the transport
protein dynein while leaving Hsp90 unchanged. Immunofluorescence and
fractionation revealed hormone-induced translocation of the
hormone-generated GR·Hsp90·FKBP52·dynein complex from
cytoplasm to nucleus, a step that precedes dissociation of the complex
within the nucleus and conversion of GR to the DNA-binding form. Taken
as a whole, these studies identify immunophilin interchange as the
earliest known event in steroid receptor signaling and provide the
first evidence of differential roles for FKBP51 and FKBP52
immunophilins in the control of steroid receptor subcellular
localization and transport.
The glucocorticoid receptor
(GR)1 is a hormone-activated
transcription factor that requires hormonally driven movement to its site of action within the nucleus. In the absence of hormone, the GR is
recovered in the cytosolic fraction of cells as an oligomeric complex
containing one molecule of receptor and two molecules of heat shock
protein 90 (Hsp90), to which the receptor binds directly (for review
see Ref. 1). An intriguing recent development, however, is that
hormone-free receptor is not found as a single, well defined complex
but exists as a mixture of complexes. Although all of these complexes
contain receptor and Hsp90, each contains only one molecule of
either FKBP52, FKBP51, Cyp40, or PP5. The latter proteins have been
classified as TPR domain proteins based on the presence of several
tetratricopeptide repeat domains that are their sites of interaction
with Hsp90 (2, 3). FKBP52, FKBP51, and Cyp40 are also members of the
immunophilin family of proteins (4-6). Thus, it is now clear that up
to four distinct receptor heterocomplexes are possible, even within the
same cell or tissue; yet almost nothing is known about the differential roles served by each immunophilin in steroid receptor responses.
It is generally accepted that the first event in hormonal activation of
GR is dissociation of hormone-bound GR from Hsp90 and the TPR proteins,
followed by nuclear translocation of the GR and all other downstream
events. Hormone-induced dissociation of the complex is a rapid event,
occurring both in the intact cell (7) and in cytosolic preparations
(8). In cytosols, dissociation of GR complexes has been shown to
require warming (typically 20-25 °C) in addition to hormone, and
this process can be blocked by molybdate and other transition metal
oxyanions (8, 9). Indeed, because of the ability of molybdate to
effectively block dissociation, it has been assumed that
molybdate-stabilized receptors are more or less "frozen" in their
native, untransformed state even when GR is bound with hormone. In this
work, we have examined this assumption by measuring the effect of
hormone on the immunophilin content of GR heterocomplexes. In so doing,
we have identified a new first step in hormonal activation of steroid receptors, i.e. hormone-induced switching of FKBP51 and
FKBP52 within the complex, showing that this event leads to movement of
the newly generated complex to the nucleus prior to its final dissociation.
Immunoadsorption of GR Complexes--
Mouse L929 cells were
grown in Dulbecco's modified Eagle's medium containing 10%
charcoal-stripped calf serum (Hyclone Laboratories, Inc.). Cells were
ruptured by Dounce homogenization in HEMG buffer (10 mM
HEPES, 3 mM EDTA, 20 mM sodium molybdate, 5%
glycerol, pH 7.4). Lysates were centrifuged at 16,000 × g for 30 min. All cytosols were used without freezing or
storage. In Fig. 1, aliquots (typically 300 µl) of cytosol were
treated with dexamethasone (Sigma), RU486 (gift from Daniel Philibert,
Hoechst Marion Roussel, Inc.), or appropriate vehicle
controls followed by the addition of FiGR, the monoclonal antibody to
GR (gift from Jack Bodwell (10)), or nonimmune mouse IgG2A
(Sigma) on ice for 6 h. Samples were rotated with 20 µl of
protein A-Sepharose at 4-8 °C overnight. The pellets were washed
three times with TEG (10 mM Tris, 3 mM EDTA,
10% glycerol, 50 mM NaCl, 20 mM sodium
molybdate, pH 7.4) followed by elution of GR complexes with 2× SDS. In
Figs. 2 and 3, all steps were the same, except hormone-treatment
occurred at the intact cell.
Gel Electrophoresis and Western Blotting--
Samples were
resolved on denaturing SDS gels using a 7-14% acrylamide gradient to
achieve maximal separation between the immunophilins and antibody heavy
chains. Transfer of the samples to Immobilon-P® membranes
(Millipore Corp.) and quantitative immunoblotting were performed as
described previously (8, 11). The BuGR2 monoclonal antibody against GR
(Affinity Bioreagents) was used to probe for receptor, and various
antibodies were used to probe for Hsp90 (H38220, Transduction
Laboratories, Inc.), FKBP52 (UPJ56 (12)), FKBP51 (PA0-021, Affinity
Bioreagents), and dynein intermediate chain (monoclonal antibody
1618, Chemicon International, Inc.). The blots were then
incubated with appropriate peroxidase- and 125I-conjugated
counter-antibodies followed by color development and autoradiography.
Immunofluorescence and Fractionation--
L929 cells grown on
coverslips were incubated at 4 °C for 3 h or 37 °C for
1 h with dexamethasone or vehicle control. Immunofluorescence was
preformed by fixation with buffered 3% formaldehyde solution at
4 °C for 12 h followed by permeabilization with 0.3% Triton X-100. Permeabilized cells were incubated with FiGR monoclonal antibody
against GR or H38220 antibody against Hsp90 at a 1:100 dilution
followed by fluorescein-conjugated secondary antibody (Calbiochem) at a
1:20 dilution. Cells were visualized using a 100× objective on a Nikon
Eclipse E800 microscope. Photographs were taken with a Sensys digital
camera. Fractionation and analysis of GR complexes was performed on
L929 cells subjected to the same conditions. Cytosolic and nuclear
fractions were prepared by Dounce homogenization as described above,
except that nuclear pellets were extracted with 500 mM NaCl
for 1 h on ice.
To test the effect of hormone on cytosolic GR complex composition,
we first measured alterations to the FKBP52 content (Fig. 1A). The results show almost
no GR-associated FKBP52 in the absence of Dex but a large increase in
FKBP52 for the hormone-bound receptor. Because the interaction of
FKBP52 with the GR occurs through the TPR-binding domain of Hsp90 and
because this domain can accommodate only one TPR protein (13), we
reasoned that increased FKBP52 could result from one of three
mechanisms: 1) stabilization of the GR-Hsp90 interaction (leading to
increased yields of Hsp90 and all other Hsp90-bound components), 2)
binding of FKBP52 to unoccupied Hsp90 within the GR complex (leaving
both Hsp90 and other TPR protein levels unchanged), or 3) displacement
of other TPR proteins from Hsp90 by FKBP52 (leaving Hsp90 levels
unchanged but the levels of other TPR proteins decreased). To test
these alternatives, we measured the amounts of FKBP51 bound to the GR in response to hormone. The results show much higher levels of GR-bound
FKBP51 in the absence of hormone than in its presence (Fig.
1A). Thus, it appears that the hormone binding event can cause a swapping of FKBP immunophilins within the GR complex, presumably at the Hsp90 TPR-binding domain.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

View larger version (63K):
[in a new window]
Fig. 1.
Hormone induces reciprocal exchange of FKBP51
and FKBP52 and co-recruitment of dynein within the GR heterocomplex
in vitro. Aliquots (300 µl) of L929 cell
cytosol were treated on ice for 3 h with 100 nM
dexamethasone (panels A and C), 100 nM RU486 (panel B), or vehicle
controls followed by immunoadsorption with FiGR antibody
(Ab) against GR (F) or nonimmune mouse IgG
(NI). Samples were split and analyzed by Western blotting
with BuGR2 antibody against GR, UPJ56 antiserum against FKBP52, PA0-021
antiserum against FKBP51, H38220 mouse monoclonal antibody against
Hsp90, and mouse monoclonal antibody 1618 against dynein
intermediate chain. HC, IgG heavy chain. D,
quantitation of relative changes in protein levels within the GR
heterocomplexes was accomplished by densitometric scanning of the
autoradiograms followed by subtraction of nonimmune (NI)
values and normalization to amount of GR protein in each
condition.
To determine whether this response occurs with antagonist, we incubated cytosols with 100 nM RU486 (Fig. 1B). Here, too, the results were the same: an apparent swapping of FKBP52 for FKBP51 in response to hormone. Thus, RU486 is not an antagonist at this early stage of GR action. Although the above results suggest that the primary effect of hormone is not to increase yields of GR-associated Hsp90, we tested this directly (Fig. 1C). The results show that Hsp90 levels within the GR complex are only marginally affected by hormone. As a further test of the FKBP interchange hypothesis, the amounts of dynein associated with the GR complex were measured in the same samples (Fig. 1C). Like FKBP52, dynein levels in the GR complexes went from almost undetectable in the absence of hormone to clearly detectable in its presence. Thus, the binding of hormone to GR not only replaces FKBP51 with FKBP52 but also causes co-recruitment of a protein, dynein, that is known to directly bind FKBP52 within its peptidylprolyl isomerase domain (14).
To test this response in the intact cell, we needed hormone treatment
conditions that would not cause dissociation of the GR complex and
concomitant conversion of the GR to the tight nuclei-bound state.
Moreover, we reasoned that if swapping of immunophilins did occur in
the intact cell, the event had to be a short-lived intermediate, as
prior studies had shown that translocation of GR and conversion to
tight nuclear binding occurred within 20 min of hormone addition in
cells maintained at 37 °C (15). To detect such an intermediate, we
simply exposed intact cells to hormone at 4 °C. In an initial
experiment (Fig. 2A), a
concentration-dependent increase in the amount of
GR-associated FKBP52 was observed, with maximal effect occurring at
~30 nM Dex. This concentration of hormone was then used
in the in vivo experiment of Fig. 2B, in which
changes to the major components of the GR complex were measured. As
expected, equal amounts of GR were recovered in the absence or presence
of hormone, as well as equal amounts of receptor-associated Hsp90. In
contrast, the pattern of receptor-bound immunophilins was similar to
that seen under in vitro conditions, namely, hormone-induced loss of FKBP51 and gain of FKBP52.
|
Given the well documented role of dynein in retrograde transport of
proteins and vesicles (16), we reasoned that hormone-directed recruitment of FKBP52 and dynein to the GR may cause transport of the
GR as a complex to the nuclear compartment. To test this possibility, we performed indirect immunofluorescence using FiGR antibody (Fig. 3A). As
expected, in cells maintained at 37 °C, treatment with 30 nM Dex caused a shift of GR from cytoplasm to nucleus.
Surprisingly, a similar Dex-induced shift of GR to the nucleus was
observed in cells maintained at 4 °C, suggesting that hormone
binding was indeed causing translocation of the GR to the nucleus even
at this low temperature. Interestingly, movement of GR to the nucleus
at 4 °C was not seen until 3 h of hormone treatment, whereas
translocation at 37 °C was much faster, occurring as soon as 20 min (data not shown).
|
If hormone could cause the GR to move to the nucleus at 4 °C, was it actually moving as a complex containing FKBP52 and dynein? To test this possibility directly, cells subjected to the same treatments used in the fluorescence studies were lysed by Dounce homogenization to yield cytosolic and nuclear extract fractions, followed by analysis of GR complex composition in each fraction (Fig. 3A). As expected, cells maintained at 4 and at 37 °C, but not exposed to hormone, yielded GR that was recovered in the cytosolic fraction as a complex containing FKBP51 but little or no FKBP52. Also as expected, GR from cells maintained at 37 °C cells and incubated with hormone was recovered predominantly in the nuclear pellet fraction without bound immunophilin, demonstrating that this treatment caused dissociation of the GR complex and conversion of the receptor to its high affinity nuclei-bound state. In contrast, GR from cells maintained at 4 °C and incubated with hormone was found in the cytosolic fraction as a complex containing FKBP52 rather than FKBP51, demonstrating that this GR, although localized to the nucleus, is not tightly bound to this cellular compartment and is released into the cytosolic fraction as a complex upon cell rupture. To test whether Dex-induced accumulation of GR in the nucleus was the result of damage to or compromised function of the nuclear pore complex at 4 °C, we examined localization of Hsp90, which is known to reside predominantly in the cytoplasm of cells (Fig. 3B). The results show cytoplasmic localization of Hsp90 at both 4 and 37 °C.
The above results indicate that hormonally induced acquisition of FKBP52 and dynein may indeed be the event that causes movement of the GR complex to this compartment. If so, this would suggest that the hormone-bound GR·Hsp90·FKBP52·dynein complex found in the nucleus at 4 °C represents an intermediate stage in the hormonal activation of GR. Further evidence to support this conclusion is the fact that when cells are first bound with hormone at 4 °C (generating the FKBP52-containing GR complex within the nucleus), subsequent warming to 37 °C causes the release of GR from the FKBP52-containing complex and conversion to the high affinity nuclei-bound state (Fig. 3C). Thus, the GR·Hsp90·FKBP52·dynein complex behaves like an intermediate in that it can proceed to the next step in the pathway.
Based on our observations, we now propose a model for the early stages
of GR signaling in which immunophilin interchange is the first
hormone-directed event, followed by movement of the hormone-altered
complex to the nucleus prior to its final dissociation in that
compartment (Fig. 4). In this model, we
depict the hormone-induced FKBP interchange (Fig. 4) as a process in
which FKBP52 directly interacts with the Hsp90 that is already bound to
GR. It is possible, however, that the hormone-bound receptor recruits a
distinct Hsp90 complex containing FKBP52 as opposed to FKBP51. The
model also does not depict whether Cyp40 and PP5 are involved in this
response. Because the stoichiometry of the FKBP exchange is unknown, it is possible that Cyp40 and/or PP5 are either displaced by FKBP52 or are
similarly recruited by hormone to the sites vacated by FKBP51. Yet, we
have not been able to detect Cyp40-containing GR complexes in L929
cells, either in the absence or presence of hormone (data not
shown). Thus, in L929 cells, hormone-induced recruitment of FKBP52 had
little effect on the Cyp40 content of receptors.
|
An important question that arises from these results is how the hormone-generated GR·Hsp90·FKBP52·dynein complex is targeted to the nucleus. An obvious candidate process is microtubule-based transport exploiting the recruitment of dynein to the complex. Consistent with this speculation is the fact that the form of dynein observed here is the dynein intermediate chain, a component of dynein motor complexes responsible for cargo binding activity (16). Yet how can this process occur at 4 °C? Obviously, we have not yet answered this question. Therefore, it remains a possibility that movement of the complex at this temperature is through passive diffusion, even though movement at physiological temperatures may occur by active transport. Transport to the nucleus aside, is it possible for GR to move into the nucleus as a complex or to reassemble on the other side? It appears that this process can occur, as a variety of hormone-free receptors are found associated with Hsp90 whether or not they reside in the cytoplasm or the nucleus (17). Moreover, it is now clear that hormone-free (18) and hormone-bound receptors (19) can freely shuttle between the nuclear and cytoplasmic compartments and that the equilibrium of these movements determines whether any given receptor is predominantly in the cytoplasm or the nucleus. Yet almost nothing is known about the factors that control this equilibrium. Our results may now provide the basis for understanding this process, as the initial function of hormone may simply be to alter the shuttling equilibrium in favor of nuclear retention of the complex, a process in which FKBP52 is responsible for nuclear localization of receptor, whereas FKBP51 directs GR to the cytoplasm.
In conclusion, we present evidence that the hormone binding event
causes an interchange of FKBP51 and FKBP52 immunophilins within the GR
heterocomplex that in turn appears to control the intracellular
trafficking of GR. This observation may have implications for many
target substrates of the Hsp90-based chaperone complex such as other
steroid receptors, unrelated transcription factors (e.g.
HSF1), protein kinases (e.g. Src and Raf), and a variety of
proteins and structures (e.g. proteosome and
G
complexes) (20-23). One such implication is that
the Hsp90 chaperone complex is needed not only for proper folding of
substrate proteins but also for subcellular trafficking of these
substrates, a function that may be regulated by differential
immunophilin content.
| |
ACKNOWLEDGEMENTS |
|---|
We acknowledge Dr. Jack Bodwell for the kind gift of FiGR antibody and Dr. Karen Leach for the gift of UPJ56 antibody.
| |
FOOTNOTES |
|---|
* This investigation was supported by National Institutes of Health Grant DK43867 (to E. R. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Present address: Dept. of Internal Medicine, Wayne State
University, Suite 2E, 4201 St. Antonine, Detroit, MI 48201-2022.
§ To whom correspondence should be addressed: Dept. of Pharmacology, Medical College of Ohio, 3035 Arlington Ave., Toledo, OH 43614-5804. Tel.: 419-383-4182; Fax: 419-383-2871; E-mail: esanchez@mco.edu.
Published, JBC Papers in Press, December 20, 2001, DOI 10.1074/jbc.C100531200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: GR, glucocorticoid receptor; Hsp90, heat shock protein 90; TPR, tetratricopeptide repeat; Dex, dexamethasone; FKBP, FK506-binding protein.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Pratt, W. B.,
and Toft, D. O.
(1997)
Endocr. Rev.
18,
306-360 |
| 2. |
Ratajczak, T.,
Carrello, A.,
Mark, P. J.,
Warner, B. J.,
Simpson, R. J.,
Moritz, R. L.,
and House, A. K.
(1993)
J. Biol. Chem.
268,
13187-13192 |
| 3. |
Radanyi, C.,
Chambraud, B.,
and Baulieu, E. E.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
11197-11201 |
| 4. |
Tai, P. K.,
Albers, M. W.,
Chang, H.,
Faber, L. E.,
and Schreiber, S. L.
(1992)
Science
256,
1315-1318 |
| 5. |
Yem, A. W.,
Tomasselli, A. G.,
Heinrikson, R. L.,
Zurcher-Neely, H.,
Ruff, V. A.,
Johnson, R. A.,
and Deibel, M. R., Jr.
(1992)
J. Biol. Chem.
267,
2868-2871 |
| 6. | Nair, S. C., Rimerman, R. A., Toran, E. J., Chen, S., Prapapanich, V., Butts, R. N., and Smith, D. F. (1997) Mol. Cell. Biol. 17, 594-603[Abstract] |
| 7. |
Mendel, D. B.,
Bodwell, J. E.,
Gametchu, B.,
Harrison, R. W.,
and Munck, A.
(1986)
J. Biol. Chem.
261,
3758-3763 |
| 8. |
Sanchez, E. R.,
Meshinchi, S.,
Tienrungroj, W.,
Schlesinger, M. J.,
Toft, D. O.,
and Pratt, W. B.
(1987)
J. Biol. Chem.
262,
6986-6991 |
| 9. |
Meshinchi, S.,
Sanchez, E. R.,
Martell, K. J.,
and Pratt, W. B.
(1990)
J. Biol. Chem.
265,
4863-4870 |
| 10. |
Bodwell, J. E.,
Orti, E.,
Coull, J. M.,
Pappin, D. J.,
Smith, L. I.,
and Swift, F.
(1991)
J. Biol. Chem.
266,
7549-7555 |
| 11. |
Wadekar, S. A., Li, D.,
Periyasamy, S.,
and Sanchez, E. R.
(2001)
Mol. Endocrinol.
15,
1396-1410 |
| 12. |
Ruff, V. A.,
Yem, A. W.,
Munns, P. L.,
Adams, L. D.,
Reardon, I. M.,
Deibel, M. R., Jr.,
and Leach, K. L.
(1992)
J. Biol. Chem.
267,
21285-21288 |
| 13. |
Owens-Grillo, J. K.,
Hoffmann, K.,
Hutchison, K. A.,
Yem, A. W.,
Deibel, M. R., Jr.,
Handschumacher, R. E.,
and Pratt, W. B.
(1995)
J. Biol. Chem.
270,
20479-20484 |
| 14. |
Silverstein, A. M.,
Galigniana, M. D.,
Kanelakis, K. C.,
Radanyi, C.,
Renoir, J. M.,
and Pratt, W. B.
(1999)
J. Biol. Chem.
274,
36980-36986 |
| 15. |
Galigniana, M. D.,
Scruggs, J. L.,
Herrington, J.,
Welsh, M. J.,
Carter-Su, C.,
Housley, P. R.,
and Pratt, W. B.
(1998)
Mol. Endocrinol.
12,
1903-1913 |
| 16. | King, S. M. (2000) Biochim. Biophys. Acta 1496, 60-75[Medline] [Order article via Infotrieve] |
| 17. |
Rexin, M.,
Busch, W.,
Segnitz, B.,
and Gehring, U.
(1992)
J. Biol. Chem.
267,
9619-9621 |
| 18. | Guiochon-Mantel, A., Lescop, P., Christin-Maitre, S., Loosfelt, H., Perrot-Applanat, M., and Milgrom, E. (1991) EMBO J. 10, 3851-3859[Medline] [Order article via Infotrieve] |
| 19. |
Madan, A. P.,
and DeFranco, D. B.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
3588-3592 |
| 20. |
Stancato, L. F.,
Chow, Y. H.,
Hutchison, K. A.,
Perdew, G. H.,
Jove, R.,
and Pratt, W. B.
(1993)
J. Biol. Chem.
268,
21711-21716 |
| 21. | Tsubuki, S., Saito, Y., and Kawashima, S. (1994) FEBS Lett. 344, 229-233[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Inanobe, A.,
Takahashi, K.,
and Katada, T.
(1994)
J. Biochem. (Tokyo).
115,
486-492 |
| 23. | Zou, J., Guo, Y., Guettouche, T., Smith, D. F., and Voellmy, R. (1998) Cell 94, 471-480[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
E. B. Binder, R. G. Bradley, W. Liu, M. P. Epstein, T. C. Deveau, K. B. Mercer, Y. Tang, C. F. Gillespie, C. M. Heim, C. B. Nemeroff, et al. Association of FKBP5 Polymorphisms and Childhood Abuse With Risk of Posttraumatic Stress Disorder Symptoms in Adults JAMA, March 19, 2008; 299(11): 1291 - 1305. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, A. F. Clark, and T. Yorio FK506-Binding Protein 51 Regulates Nuclear Transport of the Glucocorticoid Receptor {beta} and Glucocorticoid Responsiveness Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1037 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Riggs, M. B. Cox, H. L. Tardif, M. Hessling, J. Buchner, and D. F. Smith Noncatalytic Role of the FKBP52 Peptidyl-Prolyl Isomerase Domain in the Regulation of Steroid Hormone Signaling Mol. Cell. Biol., December 15, 2007; 27(24): 8658 - 8669. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Buchanan, C. Ricciardelli, J. M. Harris, J. Prescott, Z. C.-L. Yu, L. Jia, L. M. Butler, V. R. Marshall, H. I. Scher, W. L. Gerald, et al. Control of Androgen Receptor Signaling in Prostate Cancer by the Cochaperone Small Glutamine Rich Tetratricopeptide Repeat Containing Protein {alpha} Cancer Res., October 15, 2007; 67(20): 10087 - 10096. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Woodruff, H. A. Boushey, G. M. Dolganov, C. S. Barker, Y. H. Yang, S. Donnelly, A. Ellwanger, S. S. Sidhu, T. P. Dao-Pick, C. Pantoja, et al. From the Cover: Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids PNAS, October 2, 2007; 104(40): 15858 - 15863. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Periyasamy, M. Warrier, M. P. M. Tillekeratne, W. Shou, and E. R. Sanchez The Immunophilin Ligands Cyclosporin A and FK506 Suppress Prostate Cancer Cell Growth by Androgen Receptor-Dependent and -Independent Mechanisms Endocrinology, October 1, 2007; 148(10): 4716 - 4726. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Yong, Z. Yang, S. Periyasamy, H. Chen, S. Yucel, W. Li, L. Y. Lin, I. M. Wolf, M. J. Cohn, L. S. Baskin, et al. Essential Role for Co-chaperone Fkbp52 but Not Fkbp51 in Androgen Receptor-mediated Signaling and Physiology J. Biol. Chem., February 16, 2007; 282(7): 5026 - 5036. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fang, D. Ricketson, L. Getubig, and B. Darimont Unliganded and hormone-bound glucocorticoid receptors interact with distinct hydrophobic sites in the Hsp90 C-terminal domain PNAS, December 5, 2006; 103(49): 18487 - 18492. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Yang, I. M. Wolf, H. Chen, S. Periyasamy, Z. Chen, W. Yong, S. Shi, W. Zhao, J. Xu, A. Srivastava, et al. FK506-Binding Protein 52 Is Essential to Uterine Reproductive Physiology Controlled by the Progesterone Receptor A Isoform Mol. Endocrinol., November 1, 2006; 20(11): 2682 - 2694. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Smyczynski, F. Roudier, L. Gissot, E. Vaillant, O. Grandjean, H. Morin, T. Masson, Y. Bellec, D. Geelen, and J.-D. Faure The C Terminus of the Immunophilin PASTICCINO1 Is Required for Plant Development and for Interaction with a NAC-like Transcription Factor J. Biol. Chem., September 1, 2006; 281(35): 25475 - 25484. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Allan, D. Mok, B. K. Ward, and T. Ratajczak Modulation of Chaperone Function and Cochaperone Interaction by Novobiocin in the C-terminal Domain of Hsp90: EVIDENCE THAT COUMARIN ANTIBIOTICS DISRUPT Hsp90 DIMERIZATION J. Biol. Chem., March 17, 2006; 281(11): 7161 - 7171. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Schmidt, J. Rainer, S. Riml, C. Ploner, S. Jesacher, C. Achmuller, E. Presul, S. Skvortsov, R. Crazzolara, M. Fiegl, et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia Blood, March 1, 2006; 107(5): 2061 - 2069. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yan, P. Frost, Y. Shi, B. Hoang, S. Sharma, M. Fisher, J. Gera, and A. Lichtenstein Mechanism by Which Mammalian Target of Rapamycin Inhibitors Sensitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis Cancer Res., February 15, 2006; 66(4): 2305 - 2313. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, A. F. Clark, and T. Yorio Heat Shock Protein 90 Is an Essential Molecular Chaperone for Nuclear Transport of Glucocorticoid Receptor {beta} Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 700 - 708. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Magee, L.-w. Chang, G. D. Stormo, and J. Milbrandt Direct, Androgen Receptor-Mediated Regulation of the FKBP5 Gene via a Distal Enhancer Element Endocrinology, January 1, 2006; 147(1): 590 - 598. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, A. F. Clark, and T. Yorio Regulation of Glucocorticoid Responsiveness in Glaucomatous Trabecular Meshwork Cells by Glucocorticoid Receptor-{beta} Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4607 - 4616. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-J. Kim, Y. I. Park, and M.-S. Dong Effects of 2,4-D and DCP on the DHT-Induced Androgenic Action in Human Prostate Cancer Cells Toxicol. Sci., November 1, 2005; 88(1): 52 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. B. Denny, V. Prapapanich, D. F. Smith, and J. G. Scammell Structure-Function Analysis of Squirrel Monkey FK506-Binding Protein 51, a Potent Inhibitor of Glucocorticoid Receptor Activity Endocrinology, July 1, 2005; 146(7): 3194 - 3201. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cheung-Flynn, V. Prapapanich, M. B. Cox, D. L. Riggs, C. Suarez-Quian, and D. F. Smith Physiological Role for the Cochaperone FKBP52 in Androgen Receptor Signaling Mol. Endocrinol., June 1, 2005; 19(6): 1654 - 1666. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Agbemafle, T. J. Oesterreicher, C. A. Shaw, and S. J. Henning Immediate early genes of glucocorticoid action on the developing intestine Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G897 - G906. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Wochnik, J. Ruegg, G. A. Abel, U. Schmidt, F. Holsboer, and T. Rein FK506-binding Proteins 51 and 52 Differentially Regulate Dynein Interaction and Nuclear Translocation of the Glucocorticoid Receptor in Mammalian Cells J. Biol. Chem., February 11, 2005; 280(6): 4609 - 4616. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Galigniana, Y. Morishima, P. A. Gallay, and W. B. Pratt Cyclophilin-A Is Bound through Its Peptidylprolyl Isomerase Domain to the Cytoplasmic Dynein Motor Protein Complex J. Biol. Chem., December 31, 2004; 279(53): 55754 - 55759. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Harrell, P. J. M. Murphy, Y. Morishima, H. Chen, J. F. Mansfield, M. D. Galigniana, and W. B. Pratt Evidence for Glucocorticoid Receptor Transport on Microtubules by Dynein J. Biol. Chem., December 24, 2004; 279(52): 54647 - 54654. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Malone, Z. Wang, and C. W. Distelhorst The Glucocorticoid-induced Gene tdag8 Encodes a Pro-apoptotic G Protein-coupled Receptor Whose Activation Promotes Glucocorticoid-induced Apoptosis J. Biol. Chem., December 17, 2004; 279(51): 52850 - 52859. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Swales and M. Negishi CAR, Driving into the Future Mol. Endocrinol., July 1, 2004; 18(7): 1589 - 1598. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Galigniana, J. M. Harrell, H. M. O'Hagen, M. Ljungman, and W. B. Pratt Hsp90-binding Immunophilins Link p53 to Dynein During p53 Transport to the Nucleus J. Biol. Chem., May 21, 2004; 279(21): 22483 - 22489. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Jones, D. Li, I. M. Wolf, S. A. Wadekar, S. Periyasamy, and E. R. Sanchez Enhancement of Glucocorticoid Receptor-Mediated Gene Expression by Constitutively Active Heat Shock Factor 1 Mol. Endocrinol., March 1, 2004; 18(3): 509 - 520. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kobayashi, T. Sueyoshi, K. Inoue, R. Moore, and M. Negishi Cytoplasmic Accumulation of the Nuclear Receptor CAR by a Tetratricopeptide Repeat Protein in HepG2 Cells Mol. Pharmacol., November 1, 2003; 64(5): 1069 - 1075. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Lees, D. J. Peet, and M. L. Whitelaw Defining the Role for XAP2 in Stabilization of the Dioxin Receptor J. Biol. Chem., September 19, 2003; 278(38): 35878 - 35888. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tesic, J. A. Marsh, S. B. Cullinan, and R. F. Gaber Functional Interactions between Hsp90 and the Co-chaperones Cns1 and Cpr7 in Saccharomyces cerevisiae J. Biol. Chem., August 29, 2003; 278(35): 32692 - 32701. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. De Bosscher, W. Vanden Berghe, and G. Haegeman The Interplay between the Glucocorticoid Receptor and Nuclear Factor-{kappa}B or Activator Protein-1: Molecular Mechanisms for Gene Repression Endocr. Rev., August 1, 2003; 24(4): 488 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Hubler, W. B. Denny, D. L. Valentine, J. Cheung-Flynn, D. F. Smith, and J. G. Scammell The FK506-Binding Immunophilin FKBP51 Is Transcriptionally Regulated by Progestin and Attenuates Progestin Responsiveness Endocrinology, June 1, 2003; 144(6): 2380 - 2387. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cheung-Flynn, P. J. Roberts, D. L. Riggs, and D. F. Smith C-terminal Sequences outside the Tetratricopeptide Repeat Domain of FKBP51 and FKBP52 Cause Differential Binding to Hsp90 J. Biol. Chem., May 2, 2003; 278(19): 17388 - 17394. [Abstract] [Full Text] [PDF] |
||||